WASHINGTON, DC – "Employers are deeply concerned about prescription drug costs, which is why the Council has called on Congress to take bold legislative action to lower prices and increase transparency," American Benefits Council Senior Vice President, Health Policy, Ilyse Schuman said today. "Unfortunately, legislation that lowers prescription drug costs for Medicare beneficiaries – while important – is no solution if it results in higher costs for the 177 million Americans with employer-sponsored health insurance."
The American Benefits Council teamed with the Urban Institute and the Deloitte Health Equity Institute to prepare and release a report describing how health equity can be advanced through improved collection and sharing of race and ethnicity data.
Many plans and IRAs are generally facing a 12/31/22 deadline for amending their governing documents to comply with the SECURE Act. Without a prompt extension of this deadline, many plans and IRAs may need to be amended multiple times in the next few years, which would be contrary to the laudable efforts on the Hill to avoid this result in SECURE 2.0.
This Coalition letter was sent to Members of the Senate Committee on Health, Education, Labor and Pensions on S. 4353, the Retirement Improvement and Savings Enhancement to Supplement Healthy Investments for the Nest Egg Act (RISE and SHINE Act) on June 13, 2022.